PureTech’s Karuna Gets Another $68m For Re-engineered Lilly CNS Candidate
Executive Summary
Karuna Therapeutics plans to expand its development program for lead candidate KarXT beyond its current Phase II trial in schizophrenia. The series B financing follows a $42m series A in 2018.
You may also be interested in...
IPO Update: 28 Biopharma Companies Raise $3bn, Provide An Average 10% Return
Even though half of the drug developers that have gone public in the US during the first two quarters of the year are providing negative returns, the 13 companies trading in positive territory bring the class of 2019's average return to 10%.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.